Table 4.
Treatment-related adverse events between TACE-A and TACE-AP groups.
| AEs | TACE-A (N = 148) | TACE- AP (N = 68) | ||
|---|---|---|---|---|
| Any grade | ≥ grade 3 | Any grade | ≥ grade 3 | |
| Fever | 71(47.97) | 2 (1.11) | 31 (45.59) | 0 |
| Pain | 61 (41.22) | 5 (3.38) | 28 (41.18) | 2(2.94) |
| Nausea and Vomiting | 45 (30.41) | 0 | 21 (30.89) | 0 |
| Hand-foot skin reactions | 65 (43.92) | 4 (2.22) | 28 (41.18) | 3 (4.41) |
| Hypertension | 48 (32.43) | 2 (1.11) | 25 (36.76) | 1 (1.47) |
| Proteinuria | 5 (3.38) | 0 | 2 (2.94) | 0 |
| Fatigue | 10 (6.76) | 0 | 5 (7.35) | 0 |
| Hoarseness | 5 (2.70) | 0 | 1 (1.47) | 0 |
| Oral ulcer | 8 (5.41) | 0 | 2 (2.94) | 0 |
| Rash | 7 (4.73) | 0 | 1 (1.47) | 0 |
| Gastrointestinal hemorrhage | 9 (6.08) | 0 | 3 (4.41) | 0 |
| Gastrointestinal reaction | 27 (17.56) | 0 | 15 (22.06) | 0 |
| RCCEP | 0 | 0 | 1 (1.47) | 0 |
| Hypothyroidism | 0 | 0 | 9 (13.23) | 0 |
| Hyperthyroidism | 0 | 0 | 3 (4.41) | 0 |
| Pneumonia | 0 | 0 | 2 (2.94) | 1 (1.47) |
| Myocarditis | 0 | 0 | 1 (1.47) | 0 |
RCCEP, Reactive cutaneous capillary endothelial proliferation.